respiratori
cidofovir
use
treat
adenoviru
pneumonia
four
pediatr
lung
transplant
recipi
c
two
develop
bronchiol
obliteran
one
underw
retransplant
good
outcom
develop
tracheomalacia
requir
continu
lowflow
oxygen
posit
pressur
ventil
tracheostomi
urinari
tract
six
hemopoiet
stem
cell
transplant
recipi
given
cidofovir
mgkgweek
week
altern
week
minimum
four
rang
dose
three
develop
adenoviru
hepat
two
coliti
one
nephriti
c
select
graft
andor
graftversushost
diseas
count
l
patient
prehydr
brian
j
angu
antivir
drug
given
probenecid
intraven
immunoglobulin
gkgweek
follow
mgkg
altern
week
minimum
four
dose
two
patient
die
infect
four
respond
none
requir
withdraw
treatment
advers
effect
baselin
creatinin
slightli
rais
patient
hepat
improv
cidofovir
patient
transient
increas
creatinin
number
dose
increas
cidofovir
mgkgweek
mgkg
altern
day
adjust
creatinin
clear
anc
use
treat
hemopoiet
stem
cell
transplant
recipi
invas
ade
novir
infect
includ
three
pneu
monia
one
hepat
four
hemorrhag
coliti
three
hemor
rhagic
cystiti
c
concomit
intraven
immunoglobulin
coliti
addit
one
oral
immunoglobulin
ribavirin
donor
lymphocyt
infus
vari
degre
immunocompromis
pre
senc
graftversushost
diseas
leukocytedeplet
allograft
six
die
nephrotox
two
case
retrospect
studi
recipi
hemopoiet
stem
cell
transplant
mean
age
year
given
mean
rang
weekli
dose
cidofovir
mg
kg
without
probenecid
bk
virusasso
ciat
hemorrhag
cystiti
graft
versushost
diseas
take
corti
costeroid
time
diagnosi
c
signific
rise
creatinin
renal
insuffici
case
potenti
caus
case
could
cidofovir
play
role
normal
renal
function
cidofovir
recov
urin
rais
possibl
therapeut
intravesicular
administr
aciclovir
psychiatr
hemodialysi
success
use
treat
aciclovir
induc
psychosi
man
rectal
carcinoma
endstag
renal
failur
hemodialysi
given
intraven
aciclovir
develop
delirium
visual
auditori
hallucin
disorient
place
time
impair
recent
memori
recov
fulli
consecut
day
hemodialysi
urinari
tract
report
renal
insuffi
cienci
associ
use
intraven
aciclovir
continu
appear
retrospect
review
children
effect
dose
per
kilogram
age
sex
nephrotox
c
predictor
aciclovir
nephrotox
concomit
use
nephrotox
drug
impair
glomerular
filtrat
rate
gfr
baselin
fetotox
suggest
matern
use
aciclovir
may
associ
necrot
enterocol
neonat
immunolog
acut
allerg
reaction
valaciclovir
describ
woman
develop
gener
malais
diffus
pruritu
angioedema
hand
feet
reduc
conscious
faint
within
minut
take
valaciclovir
mg
genit
herp
skin
prick
test
aciclovir
posit
urinari
tract
aciclovir
renal
insuffici
report
valaciclovir
japanes
man
cardio
myopathi
chronic
renal
diseas
admit
anuria
system
edema
renal
dysfunct
take
valaciclovir
g
td
day
herp
zoster
infect
nonsteroid
antiinflammatori
drug
briefli
dialysisdepend
made
full
recoveri
adefovir
observ
studi
patient
lamivudineresist
hbe
antigen
hbeag
neg
diseas
adefovir
mg
alon
n
combin
lamivudin
n
caus
fall
creatinin
clearanc
requir
modif
adefovir
dose
two
patient
combin
therapi
underli
liver
cirrhosi
c
one
develop
reduc
liver
function
biopsi
show
steatohepat
one
adefovir
monotherapi
develop
gastric
cancer
five
combin
therapi
underli
cirrhosi
develop
hepatocellular
carcinoma
statist
signific
adefovir
mgday
combin
lamivudin
mgday
use
patient
recurr
hepat
b
viru
infec
tion
liver
transplant
c
patient
chronic
hepat
b
pretranspl
underw
period
preoper
treat
ment
periop
prophylaxi
lamivudin
hepat
b
immunoglobulin
without
adefovir
lamivudineresi
tant
patient
advers
effect
necessi
tate
drug
withdraw
one
requir
dosag
adjust
rise
creati
nine
three
recurr
hepatocellular
carcinoma
two
die
month
start
adefovir
therapi
one
continu
posit
hepat
b
viru
dna
drugdrug
interact
entacavir
interact
entacavir
mgday
adefovir
mgday
studi
fixedsequ
crossov
studi
heal
thi
adult
c
result
suggest
combin
therapi
safe
admini
tere
without
need
dosag
adjust
ment
either
drug
headach
nine
subject
dysmenorrhea
two
took
entecavir
alon
see
drug
activ
influenza
virus
ion
channel
inhibitor
drugdrug
interact
adefovir
interact
entacavir
mgday
ade
fovir
mgday
studi
fixedsequ
crossov
studi
healthi
adult
c
result
suggest
com
binat
therapi
safe
administ
without
need
dosag
adjust
either
drug
headach
nine
subject
dysmenorrhea
two
took
entecavir
alon
lamivudin
observ
studi
treatmentna
hbeagposit
children
took
lamivudin
highdos
interferon
alpha
combin
therapi
flulik
symptom
anorexia
commonest
advers
effect
weight
loss
nausea
vomit
arthralgia
loss
hair
also
note
c
open
studi
pharmacokinet
lamivudin
patient
receiv
peri
toneal
dialysi
eye
red
n
diar
rhea
n
commonest
advers
event
c
compar
studi
doubleblind
phase
iii
random
control
trial
lamivudin
mgday
n
versu
tel
bivudin
mgday
n
creatin
kinas
activ
rais
patient
receiv
ing
lamivudin
telbivudin
fell
spontan
drug
treatment
grade
lower
take
lamivudin
take
telbivudin
c
grade
rise
transaminas
treatment
frequent
lamivudin
telbivudin
observ
studi
highdos
ribavirin
outbreak
sever
acut
respira
tori
syndrom
toronto
associ
high
rate
advers
event
anemia
odd
ratio
confid
interv
ci
hypomagnesemia
ci
bradycar
dia
ci
c
risk
anemia
hypomagnesemia
bra
dycardia
attribut
ribavirin
respect
author
conclud
use
highdos
ribavirin
appropri
treatment
infecti
diseas
ribavirin
proven
clinic
efficaci
context
clinic
trial
state
ribavirin
use
empir
treatment
viral
syndrom
unknown
origin
skin
occasion
rash
area
drug
contact
conjunctiv
irrit
occur
aerosol
ribavirin
use
month
infant
immunodefici
musculoskelet
doubleblind
phase
iii
random
control
trial
lami
vudin
mgday
n
versu
telbivu
dine
mgday
n
rais
creatin
kinas
activ
common
patient
took
telbivudin
fell
sponta
neousli
drug
treatment
grade
lower
took
telbivu
dine
took
lamivu
dine
myopathi
character
muscl
pain
weak
moder
rais
crea
tine
kinas
activ
treat
ment
report
one
patient
telbivudin
therapi
month
telbivudin
withdrawn
creatin
kinas
activ
normal
within
month
symptom
resolv
month
c
cardiovascular
syncop
occur
young
man
took
tenofovir
emtricitabin
nevirapin
primari
human
immunodefici
infect
week
resolv
withdraw
antiretrovir
drug
metabol
hemochromatosi
gene
polymorph
hfe
g
possibl
mitochondri
haplogroup
j
gave
rel
protect
lipoatrophi
antiretrovir
drug
therapi
trial
patient
random
didanosin
stavudin
zidovudin
lamivudin
combin
efavirenz
nelfinavir
aid
clinic
trial
group
actg
substudi
c
stavudin
less
favor
effect
lipid
profil
caus
lipoatrophi
abacavir
versu
ran
domiz
open
trial
stratifi
viral
load
cell
count
adult
hiv
infect
assign
stavudin
n
abacavir
n
com
bine
lamivudin
efavirenz
c
doserel
increas
total
cholesterol
ldl
cholesterol
triglycerid
open
studi
seroneg
volun
teer
persist
increas
week
withdraw
c
random
control
trial
indina
vir
saquinavir
lopinavir
combin
lowdos
ritonavir
patient
med
ian
total
cholesterol
increas
mmoll
patient
highest
minimum
drug
plasma
concentr
gastrointestin
retrospect
obser
vation
studi
highli
activ
antiretrovir
therapi
haart
patient
took
indinavir
combin
zidovudin
lamivudin
develop
nausea
significantli
like
stop
take
treatment
take
zidovudin
lamivudin
tenofovir
c
longterm
followup
studi
asymptomat
hivposit
particip
week
take
combin
indinavir
lamivudin
zidovudin
stop
treat
ment
advers
effect
nausea
diarrhea
abdom
inal
pain
common
c
common
advers
event
patient
prospect
studi
oncedaili
saquinavir
ritonavir
two
nucleosid
revers
transcriptas
inhibitor
nrti
abdomin
discomfort
diar
rhea
vomit
c
similar
find
seen
investig
liver
hivhepat
c
coinfect
patient
failur
achiev
sustain
viral
respons
nrti
therapi
didanosin
stavudin
significantli
associ
worsen
hepat
fibrosi
c
multivari
analysi
didanosin
ci
failur
sustain
viral
respons
ci
remain
significantli
associ
worsen
fibrosi
retrospect
studi
hivposi
tive
subject
men
firstlin
therapi
efavirenz
lamivudin
zidovudin
women
childbear
potenti
given
nevirapin
instead
efavirenz
efavirenzbas
regimen
use
receiv
nevirapinebas
regimen
c
first
year
subject
took
isoniazid
prophylaxi
receiv
antituberculosi
therapi
month
rifam
picin
isoniazid
pyrazinamid
etham
butol
follow
month
rifampicin
isoniazid
random
sampl
test
hepat
b
surfac
anti
gen
hbsag
posit
grade
wors
hepatotox
subject
first
episod
grade
hepatotox
antituberculosi
therapi
adjust
hazard
ratio
hr
ci
hbsag
adjust
hr
ci
strongli
associ
hepatotox
howev
hepatotox
littl
impact
symp
tom
need
hospit
need
chang
antiretrovir
drug
regimen
use
isoniazid
preven
tive
therapi
antiretrovir
drug
therapi
increas
risk
hepatotox
three
adult
develop
nodular
regen
erat
liver
take
haart
regimen
contain
atazanavir
fosampr
navir
indinavir
pancrea
larg
eurosida
studi
associ
increas
incid
pancreat
cumul
exposur
antiretrovir
drug
gener
didanosin
stavudin
particular
c
presumpt
pancreat
event
individu
personyear
per
personyear
incid
among
less
year
exposur
antiretrovir
drug
includ
stavudin
didanosin
per
personyear
respect
multivari
analysi
higher
baselin
cell
count
associ
reduc
risk
pancreat
urinari
tract
hivposit
patient
start
take
tenofovir
reduc
renal
function
c
multivari
analysi
show
signific
associ
reduc
renal
function
concurr
use
amprenavir
di
danosin
age
year
lower
baselin
weight
associ
concomit
use
tenofovir
amprenavir
reduc
kidney
function
patient
acut
interstiti
nephriti
seen
renal
biopsi
three
hivposit
patient
take
amprenavir
tenofovir
resolv
drug
withdraw
random
control
trial
dinavir
saquinavir
lopinavir
combi
nation
lowdos
ritonavir
patient
appar
doserel
associ
renal
advers
event
c
immunolog
allerg
reaction
possibl
crossreact
didanosin
tenofovir
report
woman
test
posit
given
onceaday
regimen
includ
tenofovir
plu
emtricitabin
efavirenz
day
develop
diffus
rash
fever
glossiti
efavirenz
withdrawn
condit
worsen
next
day
tenofovir
emtrici
tabin
withdrawn
dramat
resolu
tion
symptom
within
hour
day
given
zidovudin
plu
didanosin
ritonavirboost
fosamprenavir
week
develop
diffus
rash
treatment
withdrawn
restart
zidovudin
didanosin
day
later
within
day
rash
appear
observ
given
zidovudin
atazanavir
day
lamivudin
lowdos
ritonavir
remain
well
except
mild
hyperbilirubinemia
next
month
fetotox
equivoc
evid
relat
utero
nrti
exposur
mitochondri
dysfunct
hivneg
children
born
hivinfect
women
hivneg
children
possibl
case
unexplain
sign
mitochondri
dysfunct
accord
perinatal
criteria
identifi
retrospect
review
c
associ
possibl
mitochondri
dysfunct
overal
utero
nrti
exposur
trimest
first
utero
nrti
exposur
estim
exact
logist
regress
case
n
significantli
like
boy
born
earlier
year
noncas
n
associ
overal
utero
nrti
exposur
mitochondri
dysfunct
unadjust
model
higher
odd
first
utero
exposur
third
trimest
lamivudin
versu
unexpos
ci
zidovudin
lamivudin
versu
unexpos
ci
among
case
noncas
adjust
year
birth
odd
first
exposur
third
trimest
lamivudin
ci
zidovudin
lamivudin
ci
significantli
higher
among
case
noncas
incomplet
data
preclud
control
possibl
confound
matern
viral
load
psychoact
drug
use
report
renal
toxic
combin
tenofovir
didanosin
children
suggest
combin
avoid
combin
saquinavir
darunavir
ritonavir
current
recommend
plasma
concentr
darunavir
increas
c
buprenorphin
atazanavir
atazanavir
ritonavir
result
increas
metabolit
concentr
buprenorphin
dosag
reduct
buprenorphin
recommend
chang
concentr
proteas
inhibitor
c
warfarin
two
patient
take
nonnucleosid
revers
transcriptas
inhibitor
nnrti
nevirapin
proteas
inhibitor
nelfinavir
lopinavir
ritonavir
two
nucleosid
analogu
high
dose
warfarin
requir
maintain
therapeut
inr
warfarin
two
enantiom
rwarfarin
swarfarin
substrat
rwarfarin
rwarfarin
swarfarin
gastrointestin
patient
aidsassoci
dementia
adc
take
optim
stabl
background
antiretrovir
therapi
includ
either
abacavir
placebo
significantli
nausea
took
abacavir
c
immunolog
three
patient
develop
pain
lymphadenopathi
shortli
start
take
abacavir
mimick
immun
reconstitut
syndrom
also
fever
rash
hlab
recov
withdraw
abacavir
abacavir
hypersensit
occur
man
switch
twicedaili
oncedaili
regimen
woman
abacavir
hyper
sensit
present
acut
fibrin
organ
pneumonia
dyspnea
hypoxia
bilater
infiltr
suscept
factor
genet
sequenc
variat
hiv
revers
transcriptas
codon
associ
host
hlab
hivinfect
antiretrovir
drugnaiv
adult
relat
codon
variat
prematur
abacavir
withdraw
investig
treat
individu
c
one
subject
b
harbor
viru
clade
b
wildtyp
amino
acid
compar
b
sensit
specif
codon
substitut
predict
hlab
respect
posit
neg
predict
valu
respect
author
argu
revers
transcriptas
codon
could
adopt
simpl
lowcost
screen
method
identifi
individu
could
safe
treat
abacavir
detect
hlab
rapidli
easili
avail
drugdrug
interact
alcohol
three
patient
possibl
reaction
alcohol
take
abacavir
one
disulfiramlik
reaction
nausea
facial
flush
tachycardia
repeatedli
rechalleng
alcohol
anoth
describ
feel
drunk
small
amount
alcohol
third
malais
increas
alcohol
intak
author
suggest
abacavir
might
inhibit
alcohol
dehydrogenas
urinari
tract
fanconi
syndrom
nephrogen
diabet
insipidu
associ
didanosin
report
man
develop
polydipsia
poli
uria
fatigu
weight
loss
take
dida
nosin
lamivudin
boost
atazanavir
year
hypophosphatemia
hypouricemia
hyperchlorem
metabol
acidosi
normal
anion
gap
normoglycem
glycosuria
lowmolecularweight
protei
nuria
plasma
antidiuret
hormon
adh
concentr
high
pgml
refer
rang
pmoll
didano
sine
replac
anoth
proteas
inhi
bitor
medic
remain
unchang
improv
slowli
drugdrug
interact
ganciclovir
suggest
ganciclovir
prodrug
valganciclovir
inhibit
purin
nucleosid
phosphorylas
pnp
similar
manner
tenofovir
increas
didanosin
concentr
reduc
efficaci
woman
hiv
cyto
megaloviru
enter
given
valganciclovir
lamivudin
didanosin
lopinavir
ritona
vir
month
viral
load
fell
less
copiesml
cell
count
l
next
month
viral
load
remain
suppress
cell
count
fell
l
symptom
didanosin
toxic
didanosin
replac
abacavir
lead
complet
recoveri
cell
count
resolu
tion
symptom
reduct
dosag
didanosin
substitut
altern
antiretro
viral
drug
may
necessari
ganciclo
vir
use
metabol
lipodystrophi
tend
occur
often
hivhepat
c
coinfect
patient
sever
weight
loss
patient
versu
patient
persist
weight
loss
week
complet
antihepat
c
viru
hcv
therapi
like
take
stavudinebas
antiretrovir
therapi
c
anoth
studi
patient
lipoatrophi
higher
drug
exposur
stavudin
control
c
reflect
higher
geometr
concentr
ratio
respect
higher
percentag
ratio
repres
drug
concen
tration
normal
popul
curv
versu
addit
durat
stavudin
therapi
independ
asso
ciat
lipoatrophi
multivari
ana
lysi
durat
stavudin
therapi
concentr
ratio
independ
correl
lipoatrophi
chang
bodi
habitu
occur
sta
vudin
withdrawn
hivposit
women
stop
take
stavudin
year
significantli
smaller
reduct
hip
thigh
circum
ferenc
compar
reduct
occur
year
stavudin
withdraw
c
stavudin
reduc
insulin
sensit
caus
mitochondri
toxic
healthi
sub
ject
particip
without
person
famili
histori
diabet
random
stavudin
mg
bd
placebo
month
insulin
sensit
significantli
reduc
stavudin
c
addit
muscl
biopsi
took
stavudin
show
signific
reduct
mtdnanuclear
dna
chang
placebotr
subject
p
mag
netic
reson
spectroscopi
studi
mito
chondrial
function
correl
measur
insulin
sensit
patient
retrospect
studi
symptomat
hyperlactatemia
associ
stavudin
median
dura
tion
month
c
nine
patient
die
die
higher
mean
lactat
concentr
versu
mmoll
mean
alt
activ
versu
ul
time
diagnosi
sur
vive
die
lower
mean
weight
surviv
versu
kg
logist
regress
mortal
associ
patient
whose
bodi
weight
kg
ci
whose
serum
lactat
mmoll
ci
dosag
regimen
metaanalysi
clinic
trial
conduct
regulatori
approv
stavudin
shown
dosag
mg
bd
equival
antivir
efficaci
evid
lower
rate
peripher
neuropathi
lipoatrophi
standard
dosag
mg
bd
suggest
appropri
dose
resourcelimit
set
reduc
dosag
stavudin
onehalf
increas
fat
mtdna
bone
densiti
decreas
lactat
concentr
studi
patient
alreadi
take
standard
dose
c
hematolog
hemoglobin
rise
hivinfect
patient
possibl
therapi
c
crosssect
cohort
studi
hemoglobin
often
rais
untreat
patient
rise
treatment
specif
attribut
zidovudin
concentr
hemoglobin
may
high
enough
lead
misdiagnosi
betathalassemia
genotox
micronucl
reticulocyt
frequenc
measur
mar
ker
chromosom
damag
hivinfect
motherinf
pair
women
taken
prenat
zidovudin
antiretrovir
drug
without
zidovudin
c
infant
receiv
zidovudin
week
venou
blood
obtain
women
deliveri
infant
day
week
month
life
cord
blood
collect
immedi
deliveri
ten
cord
blood
sampl
control
obtain
infant
hivneg
women
receiv
antiretrovir
therapi
increas
micronucl
reticulocyt
women
infant
receiv
zidovudinecontain
antiretrovir
therapi
prenat
increas
women
infant
micronucl
reticulocyt
zidovudineexpos
neonat
fell
first
month
life
valu
compar
cord
blood
control
author
conclud
transplacent
zidovudin
exposur
genotox
human
recommend
longterm
monitor
zidovudineexpos
infant
teratogen
possibl
associ
first
trimest
exposur
zidovudin
increas
risk
hypospadia
base
one
cohort
studi
report
c
among
live
birth
women
defect
identifi
babi
defect
per
live
birth
rate
defect
per
live
birth
firsttrimest
antiretrovir
drug
exposur
per
live
birth
exposur
later
pregnanc
live
birth
antiretrovir
drug
use
genit
abnorm
specif
hypospadia
significantli
increas
among
babi
born
women
firsttrimest
exposur
antiretrovir
drug
male
live
birth
compar
two
group
male
live
birth
logist
regress
suggest
use
zidovudin
first
trimest
associ
hypospadia
adjust
ci
pregnanc
pharmacokinet
studi
three
dose
zidovudin
mg
pregnanc
six
subject
plasma
zidovudin
concentr
substanti
lower
previous
report
continu
intraven
therapi
anoth
studi
four
women
took
initi
mg
dose
follow
two
mg
dose
zidovudin
auc
concentr
increas
approxim
proport
increas
dose
vari
time
cohort
pharmacokinet
result
suggest
errat
absorpt
combin
exposur
zidovudin
plu
cotrimoxazol
caus
clinic
signifi
cant
suppress
humor
immun
respons
influenza
immun
hivposit
patient
count
l
c
ribavirin
ribavirin
inhibit
format
zidovudin
triphosph
peripher
blood
monocyt
patient
week
c
urinari
tract
pilot
open
noncompar
addon
studi
patient
fail
treatment
least
two
thymidineassoci
resist
mutat
given
tenofovir
mgday
week
addit
current
fail
antiretrovir
regimen
n
one
develop
de
fanconi
syndrom
week
two
develop
grade
one
hypopho
sphatemia
c
multicent
observ
retro
spectiv
studi
hivposit
patient
take
tenofovir
patient
stop
take
tenofovir
advers
event
includ
nausea
vomit
diarrhea
headach
associ
abnorm
basal
analyt
paramet
greater
probabl
stop
ping
treatment
c
singlecent
crosssect
evalua
tion
b
microglobinuria
marker
proxim
renal
tubul
damag
hivinfect
children
tenofovir
significantli
associ
high
abnorm
valu
c
evalu
effect
advers
effect
simplif
regimen
tenofovir
lamivudin
efavirenz
haartexperienc
subject
sustain
viral
suppress
psychiatr
advers
effect
relat
efavirenz
lead
drug
withdraw
case
symptom
includ
nightmar
insomnia
nervous
anxieti
c
metabol
actg
studi
ran
domiz
placebocontrol
doubleblind
studi
design
compar
three
proteas
inhibitorspar
antiretrovir
drug
regi
men
zidovudin
lamivudin
abacavir
zidovudin
lamivudin
efavirenz
zidovudin
lamivudin
abacavir
efa
virenz
initi
treatment
infect
subject
c
modest
rise
serum
triglycerid
ldl
cholesterol
hdl
cholesterol
two
efavirenzcontain
arm
com
pare
triplenucleosid
arm
urinari
tract
renal
calculu
occur
man
take
efavirenz
contain
efavirenz
metabolit
unspecifi
protein
betweenth
eye
advers
effect
type
definit
implic
efavirenz
h
breast
cohort
studi
cambodia
patient
develop
gynecomastia
take
regimen
contain
efavirenz
c
suscept
factor
genet
efavirenz
metabol
pharmacokinet
efavirenz
studi
children
gtot
polymorph
posit
gene
affect
oral
clearanc
c
children
tt
genotyp
slower
oral
clearanc
rate
gt
genotyp
gg
genotyp
fastest
clearanc
found
children
year
age
gg
genotyp
associ
efavirenzinduc
psychosi
genet
polymorph
report
child
hivposit
girl
take
lopinavir
mg
bd
ritonavir
mg
bd
stavudin
mg
bd
didanosin
mgday
efavirenz
mgday
develop
overt
psychosi
serum
efavirenz
concentr
time
higher
expect
heterozyg
gene
polymorph
encod
isoenzym
previous
associ
reduc
clearanc
efavirenz
psychot
symptom
resolv
gradual
withdraw
efavirenz
antimalari
drug
two
healthi
volunt
took
amodiaquin
plu
artesun
efavirenz
signific
asymptomat
rise
liver
transaminas
occur
absenc
efavirenz
c
voriconazol
random
placebocontrol
twoperiod
multipledos
withingroup
fixeddos
sequenc
studi
interact
voriconazol
mg
bd
efavirenz
mgday
healthi
men
repeat
dose
efavirenz
substanti
reduc
steadyst
mean
auc
c
max
voriconazol
respect
c
repeat
therapeut
dose
voriconazol
moder
increas
steadyst
mean
auc
c
max
efavirenz
respect
voriconazol
coadminist
efavirenz
incid
advers
event
similar
efavirenz
alon
liver
hepatotox
major
problem
nevirapin
r
frequenc
larg
increas
liver
enzym
patient
take
efavirenz
wherea
patient
take
nevirapin
warn
increas
risk
hepatotox
antiretroviralna
patient
start
take
nevirapinecontain
combin
antiretrovir
therapi
issu
base
cutoff
valu
sex
howev
unclear
whether
higher
risk
also
appli
stabl
virolo
gical
suppress
patient
metaanalysi
four
publish
random
studi
patient
includ
virolog
suppress
patient
switch
nevirapinecon
tain
regimen
followup
least
month
shown
risk
hepatotox
within
first
month
low
high
count
respect
com
bine
ci
risk
hepatotox
time
dur
ing
studi
similar
group
combin
hr
ci
author
conclud
virolog
suppress
patient
switch
nevira
pine
significantli
higher
risk
hepatotox
rash
stratifi
sex
cell
count
aim
retrospect
studi
determin
whether
recommend
use
prevent
advers
effect
c
drugnaiv
patient
n
start
treatment
nevirapin
divid
two
group
high
low
count
n
respec
tive
rash
patient
group
group
hepatotox
patient
respect
author
conclud
advic
use
nevir
apin
drugnaiv
patient
increas
risk
toxic
basi
sex
cell
count
seem
use
prevent
advers
effect
retrospect
studi
patient
men
receiv
nevirapinebas
haart
regimen
c
treatment
grade
greater
increas
transaminas
activ
overal
incid
rate
case
per
personyear
led
treatment
drawal
case
retrospect
studi
pregnant
women
take
nevirapinecontain
ing
regimen
start
continu
nevirapin
first
second
trimest
ca
concurr
chronic
hepatobiliari
disord
slightli
increas
likelihood
hepatotox
seven
patient
liver
dysfunct
six
pre
viousli
hepat
c
gall
blad
der
diseas
skin
widespread
vitiligo
erythroderma
attribut
nevirapin
man
develop
erythroderma
high
fever
hepat
take
nevirapin
month
jaundic
confluent
macular
rash
arm
leg
trunk
face
histolog
show
parakeratot
epidermi
focal
spongiosi
necrot
keratinocyt
vacuolar
degener
basal
layer
togeth
moder
edema
perivascular
mononuclear
cell
infiltr
eosinophil
upper
dermi
lesion
fade
withdraw
nevirapin
administr
oral
glucocorticoid
took
around
month
final
subsid
girl
took
nevirapin
contain
regimen
month
recurr
episod
fever
cough
sore
throat
nausea
vomit
week
apart
chest
xray
show
mild
bronchial
wall
thicken
left
lower
lobe
atelectasi
mild
infiltr
temperatur
tachycardia
gener
maculopapular
confluent
blanch
rash
target
lesion
blister
conjunctiv
inject
nasal
congest
hyperem
posterior
pharynx
sever
bilater
nontend
cervic
lymph
node
liver
enlarg
cm
spleen
palpabl
white
blood
cell
count
l
mark
eosinophilia
success
treat
intraven
immunoglobulin
antiretrovir
drug
withdraw
nevirapineinduc
stevensjohnson
syn
drome
report
misdiagnos
viral
kerat
immunolog
retrospect
studi
trough
plasma
concentr
nevirapin
five
oxid
metabolit
patient
rash
liver
function
abnorm
first
week
treatment
control
match
glucocorticoid
use
cell
count
sex
race
hepat
bc
statu
casecontrol
pair
studi
c
women
significantli
greater
exposur
men
nevirapin
four
five
metabolit
week
plasma
concentr
compar
week
strong
relationship
plasma
concentr
nevirapin
five
metabolit
casedefin
event
author
comment
system
exposur
hypothes
reactiv
intermedi
immunemedi
advers
reaction
compar
case
control
compar
proport
nevirapin
exposur
pregnanc
retrospect
fivecent
comparison
women
took
nevirapin
part
combin
antiretrovir
therapi
pregnanc
elig
women
develop
rash
develop
hepatotox
includ
coexist
rash
give
combin
incid
potenti
case
nevirapin
toxic
pregnanc
c
altern
caus
rash
hepatotox
suspect
case
mother
stop
take
nevirapin
women
start
take
nevirapin
pregnanc
develop
rash
hepatotox
women
nevirapin
exposur
pregnanc
rash
suscept
factor
genet
hla
type
demograph
immunolog
suscept
factor
reaction
nevirapin
efavirenz
studi
hivposit
patient
rash
c
isol
rash
significantli
associ
case
liver
toxic
associ
percentag
cell
individu
japanes
hypersensit
reaction
nevirapin
compar
other
gener
japa
nese
popul
c
former
group
four
patient
includ
one
develop
hepatotox
hlacw
one
hlacw
among
other
three
patient
hlacw
signific
differ
fre
quenci
hla
allel
two
group
drug
dosag
regimen
nevirapin
long
halflif
could
given
day
risk
rash
concern
liver
toxic
preclud
routin
use
oncedaili
dose
howev
toler
high
concentr
nevirapin
develop
dose
increas
slowli
start
therapi
therefor
theoret
possibl
benefit
oncedaili
dose
could
achiev
without
excess
toxic
switch
oncedaili
nevirapin
sever
month
twicedaili
administr
r
howev
daufin
studi
twicedaili
regimen
zidovudin
mg
lami
vudin
mg
nevirapin
mg
compar
oncedaili
regimen
lamivudin
mg
tenofovir
mg
nevirapin
mg
c
studi
stop
earli
virolog
failur
observ
oncedaili
patient
resist
mutat
accumul
treatment
high
rate
muta
tion
sever
nnrti
resist
profil
indic
continu
viral
replic
caus
suboptim
nevirapin
plasma
trough
concentr
possibl
due
non
adher
nonbsubtyp
infect
sub
type
c
state
observ
patient
virolog
failur
author
suggest
oncedaili
dose
introduc
induct
viral
suppress
achiev
twicedaili
regimen
coadministr
nevirapin
mgday
fluconazol
mgday
result
markedli
increas
trough
plasma
nevirapin
concentr
compar
nevirapin
alon
c
retrospect
studi
patient
given
nevirapinebas
therapi
without
fluconazol
mgday
mean
nevirapin
concentr
mgl
without
fluconazol
fluconazol
one
patient
take
fluco
nazol
develop
hepat
six
take
fluconazol
develop
nevira
pinerel
rash
differ
enc
antivir
efficaci
two
group
liver
rise
serum
unconjug
bilirubin
concentr
report
pivot
phase
iii
trial
mechan
thought
direct
inhibit
bilirubin
conjug
competit
inhibit
udp
glucuronosyltransferas
patient
polymorph
ugt
gene
like
develop
hyperbilirubinemia
r
urinari
tract
indinavir
caus
nephro
lithiasi
renal
impair
result
crystal
urinari
tract
result
inflamm
continu
drug
improv
renal
function
possibl
drug
concentr
monitor
cofactor
concomit
cotrimoxazol
therapi
environment
temperatur
increas
risk
r
use
indinavir
ritonavir
lower
dose
mg
bd
seem
reduc
advers
effect
hematuria
flank
pain
occur
patient
studi
asymptomat
hivinfect
individu
took
indina
vir
longterm
followup
studi
week
c
hair
nail
paronychia
alopecia
curl
straight
hair
ingrow
toenail
attribut
indinavir
r
pregnanc
studi
pregnant
women
take
indinavir
two
women
eight
infant
develop
hepatotox
increas
concentr
indinavir
suggest
increas
intestinalhepat
activ
pregnanc
metabol
pregnant
women
take
nelfinavir
develop
gestat
diabet
compar
none
take
zidovudin
monotherapi
two
take
nrti
nnrti
risk
gestat
diabet
increas
hepat
c
begun
haart
pregnanc
c
nail
paronychia
report
case
report
occur
nelfinavir
treatment
drugdrug
interact
fluticason
cush
ing
syndrom
adren
suppress
caus
proteas
inhibitor
increas
system
glucocorticoid
concentr
iatrogen
cush
syndrom
attribut
ritonavir
interact
fluticason
girl
taken
variou
antiretrovir
drug
eventu
took
stavudin
lamivudin
ritonavir
use
inhal
fluticason
salmeterol
bronchiectasi
month
excess
weight
gain
increas
appetit
fatigu
facial
edema
mark
acn
stretch
mark
limb
abdomen
hypercholesterolemia
hypertriglyceridemia
amenorrhea
cush
syndrom
attribut
interact
fluticason
ritonavir
chang
efavirenz
gradual
improv
within
day
reduc
edema
stretch
mark
return
menstruat
similar
case
involv
girl
observ
studi
aspir
studi
healthi
volunt
took
saquinavir
ritonavir
month
develop
grade
gastrointestin
advers
effect
seven
hyperbilirubinemia
c
aspir
studi
hyperbilirubinemia
healthi
volunt
tipranavir
nonpeptid
proteas
inhibitor
approv
use
patient
resist
strain
hiv
r
r
pharmacokinet
efficaci
advers
effect
children
adolesc
review
r
use
combin
ritonavir
observ
studi
multicent
doubleblind
random
dosefind
trial
ritonavirboost
tipra
navir
patient
common
advers
event
diarrhea
nausea
vomit
fatigu
headach
c
hematolog
tipranavir
boost
ritonavir
caus
increas
risk
bleed
ing
hivinfect
patient
hemophilia
c
intracrani
hemorrhag
report
patient
take
tipranavir
liver
tipranavir
associ
excess
grade
rise
liver
enzym
compar
ritonavirboost
proteas
inhibitor
r
pancrea
acut
pancreat
associ
hypertriglyceridemia
report
patient
take
tipranavir
ritonavir
man
take
tenofovir
mgday
trizivir
zidovudin
lamivudin
abacavir
one
tablet
bd
tipranavir
mg
bd
ritonavir
mg
bd
drank
six
standard
alcohol
drink
day
admiss
develop
mark
tender
epigastr
region
rais
serum
lipas
iul
refer
rang
iul
abdomin
comput
tomographi
ct
scan
show
pancreat
edema
peripancreat
fluid
consist
acut
pancreat
ultrasonographi
show
mildli
dilat
common
bile
duct
evid
cholelithiasi
ct
cholangiographi
show
evid
gallston
pancreat
presum
diagnosi
alcoholinduc
pancreat
manag
conserv
withdraw
medic
intraven
fluid
slow
resumpt
oral
intak
howev
within
day
develop
sever
epigastr
pain
deni
alcohol
use
serum
concentr
triglycerid
mmoll
retrospect
test
blood
sampl
taken
earlier
ill
also
show
mark
hypertriglyceridemia
tipranavir
ritonavir
withdrawn
efavirenz
given
tenofovir
trizivir
continu
triglycerid
concentr
fell
mmoll
week
later
mmoll
month
later
without
specif
intervent
skin
porphyria
cutanea
tarda
report
introduct
tipranavir
ritonavir
backbon
tenofovir
lamivudin
heterosexu
woman
switch
tipranavircontain
therapi
virolog
failur
day
develop
rash
accompani
nausea
vomit
malais
hyperamylasemia
antiretrovir
drug
withdrawn
improv
treatment
restart
although
lesion
resolv
sever
blister
appear
hand
mainli
finger
along
itch
skin
fragil
arm
aciclovir
ineffect
month
later
itch
blister
worsen
urin
concentr
protoporphyrin
coproporphyrin
time
higher
normal
drug
resist
virolog
respons
rate
tipranavirtr
individu
reduc
isol
substitut
amino
acid
posit
present
baselin
c
addit
virolog
respons
rate
tipranavir
reduc
number
baselin
proteas
inhibitor
mutat
five
individu
took
tipranavir
without
concomit
enfuvirtid
five
baselin
proteas
inhibitor
mutat
began
lose
antivir
respons
week
howev
individu
take
enfuvirtid
tipranavir
achiev
log
reduct
viral
load
baselin
week
even
five
baselin
proteas
inhibitor
mutat
virolog
respons
rate
tipranavir
reduc
baselin
phenotyp
tipranavir
greater
threefold
shift
effect
concentr
ec
refer
common
proteas
inhibitor
mutat
associ
virolog
failur
drugdrug
interact
interact
tipranavir
ritonavir
review
r
tipranavir
metabol
tipranavir
ritonavir
vitro
inhibit
induc
glucuronidas
p
glycoprotein
inhibitor
ritonavirboost
tipranavir
alon
combin
compar
proteas
inhibitor
studi
hivinfect
patient
c
psychiatr
oseltamivirinduc
worsen
delirium
report
old
man
whose
symptom
resolv
day
withdraw
japanes
author
advis
use
oseltamivir
adolesc
age
year
two
suicid
report
neuropsychiatr
event
identifi
postmarket
sur
veillanc
includ
delirium
convuls
enceph
r
howev
clear
whether
event
due
influenza
drug
phase
iii
trial
similar
incid
neurolog
cal
psychiatr
event
treat
untreat
patient
r
patient
enrol
japanes
neuramini
dase
inhibitor
treatment
studi
neuropsychiatr
symptom
case
start
treatment
c
us
food
drug
administr
fda
european
medicin
agenc
ema
advis
doctor
monitor
patient
abnorm
behavior
throughout
treat
ment
r
gastrointestin
acut
hemorrhag
coliti
associ
oral
oseltamivir
man
develop
abdomin
pain
diarrhea
hematochezia
take
two
dose
oseltamivir
systemat
review
three
trial
neuraminidas
inhibitor
prevent
treat
influenza
children
laboratoryconfirm
influenza
took
oseltamivir
vomit
often
untreat
children
withdraw
rare
requir
drug
resist
resist
occur
healthi
adult
occur
often
children
one
studi
although
lower
dosag
regimen
use
studi
resist
often
seen
among
immunocompromis
patient
report
two
eight
patient
infect
associ
fatal
outcom
resist
associ
loss
fit
r
widespread
resist
emerg
influenza
remain
seen
whether
circul
sustain
emerg
oseltamivirsensit
swine
suscept
factor
genet
evid
differ
auc
oseltamivir
activ
metabolit
oseltamivir
carboxyl
japanes
subject
caucasian
subject
children
age
year
old
adult
c
systemat
review
metaanalysi
advers
effect
zanamivir
children
show
wors
placebo
compar
studi
random
control
trial
patient
chronic
hepat
c
treat
interferonalfa
alon
n
amantadin
mg
bd
n
ribavirin
n
amantadin
ribavirin
n
sustain
virolog
respons
respect
c
statist
differ
interferon
amantadin
tripl
therapi
interferon
ribavirin
tripl
therapi
spectra
frequenc
advers
effect
similar
four
treatment
arm
howev
six
patient
withdrew
advers
effect
three
arm
contain
amantadin
two
group
nonrespond
hcv
genotyp
chronic
infect
take
interferon
ribavirin
without
amantadin
mgday
viral
load
fell
markedli
group
take
tripl
therapi
includ
amantadin
respons
rate
end
treatment
signifi
cantli
differ
c
although
analysi
viral
ion
channel
show
select
pressur
therapi
specif
resi
due
appear
link
effect
amantadin
viru
author
sug
gest
impli
antivir
effect
amantadin
nonspecif
relat
reduc
endosom
acidif
therefor
reduc
transport
hepat
c
phdepend
pathway
multicent
studi
nonrespon
der
chronic
hepat
c
random
interferon
monotherapi
n
dual
ther
api
ribavirin
n
tripl
therapi
addit
amantadin
mgday
n
amantadin
increas
frequenc
sever
advers
effect
c
patient
chronic
hepat
c
genotyp
high
viral
load
treat
interferonbeta
week
follow
interferonalfa
ribavirin
amantadin
mgday
week
sustain
virolog
respons
one
patient
stop
take
amantadin
advers
effect
lightheaded
c
renal
transplant
recipi
chronic
hepat
c
dose
ribavirin
monotherapi
n
ribavirin
amantadin
n
adjust
accord
creatinin
clearanc
c
differ
treatment
group
respect
liver
enzym
hepat
c
viremia
liver
tolog
renal
function
anemia
main
advers
effect
notabl
creatinin
clearanc
ml
minut
advers
effect
includ
leukopenia
mood
disord
profus
sweat
one
receiv
combin
therapi
still
take
aman
tadin
month
two
complet
treatment
ribavirin
alon
four
take
monotherapi
complet
treat
ment
neither
regimen
clearli
superior
treatment
studi
small
probabl
underpow
sensori
system
postmarket
surveil
studi
patient
new
diagnosi
corneal
diseas
new
prescript
amantadin
year
patient
develop
fuch
dystrophi
corneal
edema
c
rel
risk
corneal
edema
ci
patient
diagnosi
made
first
month
drug
resist
amantadin
unreli
manag
influenza
emerg
widespread
resist
notabl
subtyp
subtyp
season
remain
sensit
amantadin
r
